AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04726761 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ambulatory Blood Pressure Monitoring, non-frequent/frequent
Description: Patient will have a Spacelabs 90217 attached. This device can automatically measure the blood pressure over 24 hours. Patients will have their blood pressure measured first with a non-frequent interval, and then a frequent interval.
Study NCT06564610 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus abdominis block
Description: The block will be performed by the surgeon by injecting local anesthetic at the beginning of surgery under the guidance of the laparoscope.
Study NCT06564610 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae block
Description: The block will be performed by the anesthetist by injecting local anesthetic after induction of anesthesia under the guidance of the ultrasound.
Study NCT06564610 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Laparoscopic bariatric procedure will be performed
Study NCT06564610 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: Laparoscopic bariatric procedure will be performed
Study NCT06564610 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: An endotracheal tube will be inserted as a part of general anesthesia to all patients
Study NCT06564610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation
Description: An endotracheal tube will be inserted as a part of general anesthesia to all patients
Study NCT06564610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The patients will receive propofol for induction of anesthesia
Study NCT06564610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: The patients will receive propofol for induction of anesthesia
Study NCT06182670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gingival Former Abutment
Description: GFA is positioned on the sub-crestal implant during the surgery and it is no longer removed. This follows the one abutment one time concept and should prevent bone loss and transmucosal tunnel.
Study NCT06182670 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subcrestal Implant
Description: Placement of the endosseous sub-crestal dental implant through dedicated drills with 35 Newton insertion torque. It is positioned 2 mm under the crestal bone.
Study NCT06182670 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Healing Abutment
Description: A healing abutment is positioned on crestal implant during surgery. It is removed at prosthetic finalization.
Study NCT06182670 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prosthetic Crown
Description: A zirconia prosthetic crown finalizes the implant rehabilitation.
Study NCT06182670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prosthetic Crown
Description: A zirconia prosthetic crown finalizes the implant rehabilitation.
Study NCT06182670 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Crestal Implant
Description: Placement of the endosseous crestal implant through dedicated drills with 35 Newton insertion torque at level of the alveolar bone.
Study NCT06112210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HBOT group
Description: The HBOT will be performed in a Barox HBOT chamber (Yaklasim Makina San. Ve Tic. Ltd. Sti). Participants will be taken to the chamber immediately after the football match, where they will sit in individual chairs, and oxygen will be delivered through individual masks. The HBOT group will be exposed to 100% oxygen at 2.2 ATA (atmospheres absolute). Session will last 70 minutes.
Study NCT06112210 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CON group
Description: The placebo protocols will be performed in a Barox HBOT chamber (Yaklasim Makina San. Ve Tic. Ltd. Sti). Participants will be taken to the chamber immediately after the football match, where they will sit in individual chairs, and oxygen will be delivered through individual masks. The CON group will be exposed to normobaric ambient pressure (1 ATA). The session will last 70 minutes.
Study NCT05636540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FluorThanatrace ([18F]FTT)
Description: A pre-treatment 18F-FluorThanatrace (\[18F\]FTT) positron emission tomography/computed tomography (PET/CT) scan will be done prior to surgery or systemic therapy.
Study NCT05673369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-387
Description: 1 Tablet
Study NCT05673369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D484
Description: 1 Tablet
Study NCT05417126 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gene Therapy-vMCO-010
Description: The vMCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette
Study NCT05445830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-Intensity-Interval-Exercise
Description: Subjects will perform high-intensity-interval exercise, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
Study NCT05445830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity-Continuous-Exercise
Description: Subjects will perform moderate intensity continuous exercise, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
Study NCT05445830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Subjects will perform a series of a whole-body resistance exercises, where the acute exercise responses will be closely monitored, including measurements of O2 saturation, heart rate, blood pressure, borg scale and blood lactate. In addition, symptoms via multiple validated questionnaries and blood samples will be collected before, immediately after each exercise session to describe leukocyte and cytokine release as well as systemic metabolism. After a 48-hour rest period subjects will return to the laboratory for symptom assessment, submaximal exercise response (CPET), and blood sampling.
Study NCT05445830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Baseline assessment
Description: Subjects will perform a series of baseline assessment including neurophysiological function, circulatory and vascular function, blood volume assessment, respiratory/ventilatory function, maximal oxygen uptake, strength, physical function and fitness, blood status and muscle biopsy.
Study NCT05445830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1 year follow-up
Description: Subjects will perform the same series of baseline assessment in 1-year time, including neurophysiological function, circulatory and vascular function, blood volume assessment, respiratory/ventilatory function, maximal oxygen uptake, strength, physical function and fitness, blood status and muscle biopsy.
Study NCT06327477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06327477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06327477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06327477 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IG-IMRT
Study NCT06327477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection
Study NCT06327477 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Spatially-fractionated Radiation Therapy
Description: Undergo P-SFRT
Study NCT05137418 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine,Inactivated
Description: The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection
Study NCT06173986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1inhibitor
Description: PD-1 inhibitor, Q3W, until disease progression or unacceptable toxicity or treatment reaches 1 year
Study NCT06173986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel + cisplatin
Description: Induction phase: nab-paclitaxel + cisplatin, Q3W × 2 cycles; Concurrent ICRT phase: nab-paclitaxel + cisplatin, QW × 5 cycles
Study NCT06173986 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Primary tumor and metastatic lymph nodes, DT:45-50Gy/25fx, starting within 4 weeks following the completion of the last induction immunochemotherapy cycle
Study NCT06539039 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non surgical periodontal therapy
Description: participants received full mouth one stage debridement using hand instruments and use of universal curette for sub gingival debridement and ultrasonic scalers through use of supragingival and subgingival ultrasonic tips
Study NCT05267184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular treatment of the middle meningeal artery
Description: The middle meningeal artery on the same side(s) as the chronic subdural hematoma is embolized with liquid embolic agents.
Study NCT05267184 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard neurosurgical hematoma evacuation
Description: Standard neurosurgical evacuation of chronic subdural hematoma through burr-hole or mini craniotomy and postoperative subdural or subgaleal drainage.
Study NCT05033379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Importance of sleep
Study NCT05033379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience coaching
Description: Arena Strive
Study NCT06280027 — intervention group
Intervention type: OTHER
Intervention: survey
Description: An online survey was generated to quantitatively evaluate the level of esthetic perception.
Study NCT06515717 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ketone ester
Description: oral supplement
Study NCT06515717 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: dextrose (placebo)
Description: oral supplement calorie and taste matched to ketone supplement
Study NCT05628766 — intervention group
Intervention type: OTHER
Intervention: complete blood count
Description: Thiol/disulphide levels in the blood will be checked by taking complete blood count
Study NCT05244174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pancreatic stent
Description: Insertion of a pancreatic stent during ERCP to improve pancreatic secretion
Study NCT05244174 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatic stent
Description: Insertion of a pancreatic stent during ERCP to improve pancreatic secretion
Study NCT05614479 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GATEKEEPER intervention
Description: Agents will identify candidates in their areas of work (e.g., associations of elderly people).~Training sessions will be held for healthcare professionals and community agents.~Dissemination of materials, resources, and channels to contact and inform candidates to invite them to participate in the study. Recruitment procedures posters, leaflets, videos, newsletters, or appointments will be used.~Candidates interested and accepted will download the application on their mobile devices and will surf on the app which pretends to promote healthy aging. Users will provide some data and complete questionnaires (available in the application) for the baseline and final assessment.~Professionals will visualize how and how much participants are interacting by using the MAHA dashboard.
Study NCT06122649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apremilast
Description: Oral tablet
Study NCT06122649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablet
Study NCT05323409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPTIMISE
Description: OPTIMISE is a multilevel intervention that seeks to improve patient activation for comorbidity self-management during cancer treatment and coordination of care between oncologists and primary care physicians from point of diagnosis through the first year of post-treatment survivorship.
Study NCT06496828 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biologically-oriented preparation technique
Description: The preparation will be made according to the new principles of biologically oriented technique to receive monolithic and bi-layered all-ceramic crowns.
Study NCT06496828 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional method of preparation
Description: Teeth prepared with shoulder margins to receive monolithic and bi-layered all-ceramic crowns
Study NCT05840601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pointdexter
Description: Commercially available prosthetic hand modified with the investigational Pointdexter finger in place of the usual index finger.
Study NCT05840601 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Unmodified commercially available prosthetic hand.
Study NCT05966259 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention Group- Intensive Multilevel Intervention
Description: intensive multilevel intervention, with a minimum of 26 contact hours, for a period of 5 months. The children will be re-evaluated in the eighth month (three months after intervention) and in the eleventh month (six months after intervention). The monthly activities were composed of four weekly contacts: Individual Attendance, Food and Nutrition Education (at home), Group Food and Nutrition Education in the basic health unit and Telephone monitoring. There will be five monthly themes: food, physical activity, sedentary behavior, sleep, and mental health.
Study NCT05966259 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: The children in the Control Group were followed in a similar way, observing the activities so that they did not exceed 26 hours of contact, during the 5 months.
Study NCT06495125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avutometinib
Description: Given PO
Study NCT06495125 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06495125 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06495125 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06495125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: Given PO
Study NCT06495125 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT06495125 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT06540612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise is a set of physical activities that work large muscle groups continuously and rhythmically.
Study NCT06540612 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity counseling
Description: Physical activity counselling is a service that provides personalized guidance and support to help individuals adopt a healthy lifestyle.
Study NCT05495360 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplement
Description: twice daily serving of the study product
Study NCT05243966 — intervention group
Intervention type: DEVICE
Intervention: Myriad Matrix™ and Myriad Morcells™
Description: Ovine forestomach matrix sheet graft and morselized extracellular matrix
Study NCT05785026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menthol inhalation
Description: 300 milligrams of L-menthol will be deposited on to a cellulose swab and secured inside the lower portion of a sealed facemask.
Study NCT05785026 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Strawberry scent
Description: 600 microliters of 100% natural strawberry flavoring will be deposited onto on to a cellulose swab and secured inside the lower portion of a sealed facemask.
Study NCT04671160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment the activity of anti-Xa factor.
Description: Assessment the activity of anti-Xa factor in patients treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis, patients treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis, patients not treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis and patients not treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis.
Study NCT05348707 — intervention group
Intervention type: OTHER
Intervention: epidemiology
Description: To review medical records to describe diagnosis and severity of the disease.
Study NCT05348707 — intervention group
Intervention type: OTHER
Intervention: epidemiology
Description: To compare pre and per Covid-19 epidemics in terms of numbers of admissions and proportion of severe disease.
Study NCT04363294 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PYP scan
Description: 99mTc-labeled pyrophosphate
Study NCT05677984 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Awaken prone positioning ventilation
Description: patients were mandated to keep a prone position for at least 12 hours.
Study NCT04631822 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anaesthesia
Description: spinal anesthesia shall be conducted with 2.5 ml 0.5% hyperbaric bupivacaine at the L3/4 interspaces in the setting position.
Study NCT04631822 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided Adductor Canal Block + dexamethasone
Description: Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention. A high-frequency linear ultrasound transducer was placed transverse to the longitudinal axis of the extremity at the midthigh level at a distance approximately halfway between the iliac spine and the patella. The femoral artery was identified underneath the sartorius muscle with the vein just underneath the artery. At this position, the saphenous nerve was placed lateral to the artery in the adductor canal (Fig. 1). A 10 cm Tuohy canula 18G Gauge (Braun Medical, Melsungen, Germany) was inserted, in plane, from the lateral side of the transducer, through the sartorius muscle with the tip placed lateral to the artery. then, a 20-ml mixture of 0.25% bupivacaine, and 4 mg dexamethasone will be injected.
Study NCT04631822 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided Adductor Canal Block + dexmedetomedine
Description: Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention. A high-frequency linear ultrasound transducer was placed transverse to the longitudinal axis of the extremity at the midthigh level at a distance approximately halfway between the iliac spine and the patella. The femoral artery was identified underneath the sartorius muscle with the vein just underneath the artery. At this position, the saphenous nerve was placed lateral to the artery in the adductor canal (Fig. 1). A 10 cm Tuohy canula 18G Gauge (Braun Medical, Melsungen, Germany) was inserted, in plane, from the lateral side of the transducer, through the sartorius muscle with the tip placed lateral to the artery.then, a 20-ml mixture of 0.25% bupivacaine, and 0.5 Mg/kg dexmedetomidine will be injected.
Study NCT04631822 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided Adductor Canal Block
Description: Ultrasound blocks will be done immediately after spinal anesthesia, before surgical intervention. A high-frequency linear ultrasound transducer was placed transverse to the longitudinal axis of the extremity at the midthigh level at a distance approximately halfway between the iliac spine and the patella. The femoral artery was identified underneath the sartorius muscle with the vein just underneath the artery. At this position, the saphenous nerve was placed lateral to the artery in the adductor canal (Fig. 1). A 10 cm Tuohy canula 18G Gauge (Braun Medical, Melsungen, Germany) was inserted, in plane, from the lateral side of the transducer, through the sartorius muscle with the tip placed lateral to the artery.then, a 20-ml mixture of 0.25% bupivacaine